Related Experiment Video
Updated: May 13, 2026
09:44
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Chronic acetaminophen exposure in pediatric acute liver failure
Mike A Leonis1, Estella M Alonso, Kelly Im
1Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. mike.leonis@cchmc.org
Pediatrics
|February 27, 2013
Summary
Children with chronic acetaminophen (APAP) exposure had worse outcomes than single exposure but better than no exposure. Further research is needed to understand this acetaminophen hepatotoxicity paradox.
Area of Science:
- Pediatric Hepatology
- Pharmacology
- Clinical Toxicology
Background:
- Acetaminophen (N-acetyl-p-aminophenol [APAP]) is a common analgesic linked to hepatotoxicity.
- Understanding APAP's impact on children requires examining chronic exposure (CE) patterns.
- The Pediatric Acute Liver Failure (PALF) Study provides data on pediatric liver injury.
Purpose of the Study:
- To characterize children with chronic APAP exposure (CE) within the PALF Study.
- To compare clinical characteristics and outcomes of CE versus single exposure (SE) and no exposure (NE) groups.
- To investigate the clinical profile and outcomes associated with chronic APAP use in pediatric patients.
Main Methods:
- Analysis of 895 children enrolled in the PALF Study (2002-2009).
- Categorization into CE (≥2 days APAP), SE (<2 days APAP), and NE groups.
- Comparison of demographic, laboratory, and survival data between exposure groups.
Main Results:
- CE patients were younger, less female, and more Hispanic than SE patients.
- CE group showed lower bilirubin and higher alanine aminotransferase (ALT) than NE.
- Survival without liver transplantation at 21 days was worse for CE than SE (68% vs 92%) but better than NE (49%).
Conclusions:
- Children with chronic APAP exposure exhibit distinct clinical features compared to unexposed or acutely exposed peers.
- Outcomes for chronic APAP exposure were intermediate, worse than single exposure but better than no exposure.
- The unexpected survival advantage in the chronic exposure group warrants further investigation into underlying mechanisms.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...